Hompage Sliders (32)

Join The Only Dedicated Community for Preclinical Oncology Scientific Innovations To Arm Your Future Clinical Success

We have witnessed numerous experimental preclinical models over the last few years due to technology advancements. However, only a few can truly answer specific immunological questions, particularly in the immuno-oncology field. As regulatory agencies increasingly demand more physiologically relevant data as part of the filing package, a well-designed and -validated genetically engineered model can offer preclinical and translational scientists distinct insights into and understanding of human physiological relevance, maximizing clinical predictability.

The PREDiCT Innovation: Advancing Precise & Translational Preclinical Models for Evaluating Immunotherapies meeting, in partnership with genOway, shared the latest techniques and strategies in preclinical modeling.

Chaired by Niina Veitonmaki, Head of Biology, Aelin Therapeutics, these are just a snapshot of the unmissable takeaways:

  • Uncover which humanized models and gene targeting optionsare best for your study objective
  • Measure key physiological parametersto enhance your PKPD understanding, which is critical to translational and safety studies
  • Explore how to induce human cytokine release in humanized BRGSF mice to mimic immune response

Expert Speakers Included:

Who Attended?

CxO, VP, Director, Head, Principal, Team Leader of:

  • Preclinical Science
  • Preclinical Biomarkers
  • Translational Science
  • Immunologists
  • RNA/Genomic Sequencing
  • Toxicology
  • Target Validation
  • Safety

From oncology drug developers who specialize in:

  • Targeted & Combination Therapies
  • Immuno-oncology
  • Immuno-inflammation
  • Autoimmunity

This Bespoke Innovation Virtual Meeting is Designed With and Supported By:

genOway Logo

genOway is a global biotechnology company dedicated to improve the predictability and reliability of preclinical data through the development and commercialization of unique, innovative, genetically modified models with high physiological relevancy.

With a growing catalog of humanized immune checkpoint mouse and cell line models, and reconstituted mice featuring a human immune system, genOway offers a broad set of tools to study mechanism of actions, efficacy, and safety of immunotherapies aiming to enhance translatability toward the clinic.

Founded in 1999, genOway serves clients in 380 academic institutions and 170 life sciences companies, including 17 of the top 20 pharma.

Learn more here: www.genoway.com